1) Jose-Maria Fernandez proposes a "cancer megafund" that would invest in early-stage cancer research and development, spreading risk across 150 experimental treatments to attract serious investment and potentially generate profits to fund treatments that fail. 2) Duncan Higgons and Michael Davies debate the challenges of fundraising for healthcare ventures, noting the large costs involved, risk of failure, and lack of sexiness of some areas. 3) Jose-Maria argues that the megafund structure could make returns and risks depend more on scientific progress than financial markets, and that it has potential to be economically viable and profitable for investors based on simulations of cancer drug development over 20 years.